Royalty Pharma plc RPRX
5 trading plans running, 37 Form 144 notices for $144.3M
10-Q, 10-K and Form 144What RPRX's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Aug 20, 2025 to Mar 12, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Chris Hite Executive Vice President & Chairman, Partnering & Investments |
Adopted 10b5-1 plan | Sep 21, 2026 | 10-Q Nov 4, 2026 | ||
| Marshall Urist, M.D., Ph.D. Executive Vice President, Research & Investments |
Adopted 10b5-1 plan | Aug 7, 2026 | 10-Q Nov 4, 2026 | ||
| Terrance Coyne Executive Vice President & Chief Financial Officer |
Adopted 10b5-1 plan | Aug 6, 2026 | 10-Q Nov 4, 2026 | ||
| Marshall Urist, M.D., Ph.D. Executive Vice President, Research & Investments |
Adopted 10b5-1 plan | Jun 26, 2026 | 10-Q Aug 5, 2026 | ||
What the company wroteThe following table describes the written plans for the sale of our Class A ordinary shares adopted or terminated by our executive officers and directors during the second quarter of 2026, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”): Name and Title Action Adoption/ Termination Date Scheduled Expiration Date of Trading Plan (1) Maximum Shares Subject to Trading Plan Marshall Urist, M.D., Ph.D. Executive Vice President, Research & Investments Adoption June 26, 2026 October 9, 2026 EPA Shares (2) (1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan. (2) On June 26, 2026, Dr. Urist entered into a Trading Plan, scheduled to commence on September 28, 2026 and end on October 9, 2026, providing for the sale of up to 100% of the Class A ordinary shares that may be issued upon settlement of EPAs in August 2026. | |||||
| Christopher Hite Executive Vice President & Chairman, Partnering & Investments |
Adopted 10b5-1 plan | Mar 20, 2026 | 10-Q May 6, 2026 | ||
| Terrance Coyne Executive Vice President & Chief Financial Officer |
Adopted 10b5-1 plan | Feb 24, 2026 | 10-Q May 6, 2026 | ||
| Gregory Norden Director |
Adopted 10b5-1 plan | Feb 12, 2026 | 10-Q May 6, 2026 | ||
| Marshall Urist, M.D., Ph.D. Executive Vice President, Research & Investments |
Adopted 10b5-1 plan | Feb 12, 2026 | 10-Q May 6, 2026 | ||
| Marshall Urist, M.D., Ph.D. Executive Vice President, Research & Investments |
Adopted 10b5-1 plan | Sep 16, 2025 | 10-Q Nov 5, 2025 | ||
| George Lloyd Executive Vice President, Investments & Chief Legal Officer |
Adopted 10b5-1 plan | Aug 20, 2025 | 10-Q Nov 5, 2025 | ||
| Terrance Coyne Executive Vice President & Chief Financial Officer |
Adopted 10b5-1 plan | Aug 8, 2025 | 10-Q Nov 5, 2025 | ||
| Marshall Urist Executive Vice President, Research and Investments |
Ended 10b5-1 plan | Mar 21, 2024 | 10-Q May 9, 2024 | ||
| Terrance Coyne Executive Vice President & Chief Financial Officer |
Ended 10b5-1 plan | Mar 6, 2024 | 10-Q May 9, 2024 | ||
| Marshall Urist Executive Vice President, Research and Investments |
Adopted 10b5-1 plan | Dec 20, 2023 | 10-K Feb 15, 2024 | ||
| Terrance Coyne Executive Vice President & Chief Financial Officer |
Adopted 10b5-1 plan | Nov 22, 2023 | 10-K Feb 15, 2024 | ||
| Marshall Urist Executive Vice President, Research and Investments |
Adopted 10b5-1 plan | Sep 29, 2023 | 10-Q Nov 8, 2023 | ||
| Rory Riggs Director |
Adopted 10b5-1 plan | Sep 29, 2023 | 10-Q Nov 8, 2023 | ||
| Terrance Coyne Executive Vice President & Chief Financial Officer |
Ended 10b5-1 plan | Sep 12, 2023 | 10-Q Nov 8, 2023 | ||
Show the other 10 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Oct 5, 2026 | Urist Marshall Officer |
4,126 | $236K |
| Sep 28, 2026 | Urist Marshall Officer |
4,126 | $239K |
| Sep 22, 2026 | SCH Investment Partners LLC Officer |
100,000 | $5.8M |
| Aug 18, 2026 | SCH Investment Partners LLC Officer |
100,000 | $6.0M |
| Aug 13, 2026 | Terrance Coyne Officer |
11,002 | $644K |
| Aug 12, 2026 | Errol B. De Souza Former Affiliate |
206,352 | $11.9M |
| Aug 12, 2026 | Errol B. De Souza Former Affiliate |
125,000 | $7.2M |
| Jul 1, 2026 | Urist Marshall Officer |
9,099 | $508K |
| Jul 1, 2026 | SCH Investment Partners LLC Officer |
100,000 | $5.7M |
| Jun 24, 2026 | Urist Marshall Officer |
9,098 | $502K |
| Jun 23, 2026 | Christopher Hite Officer |
30,000 | $1.7M |
| Jun 23, 2026 | SCH Investment Partners LLC Officer |
150,000 | $8.2M |
| May 26, 2026 | Terrance Coyne Officer |
64,399 | $3.5M |
| May 20, 2026 | Urist Marshall Officer |
13,684 | $722K |
| May 14, 2026 | Norden Gregory Officer |
3,045 | $161K |
| May 14, 2026 | Urist Marshall Officer |
13,684 | $726K |
| Apr 28, 2026 | Terrance Coyne Officer |
34,791 | $1.7M |
| Apr 1, 2026 | Terrance Coyne Officer |
34,791 | $1.7M |
| Mar 23, 2026 | Terrance Coyne Officer |
34,791 | $1.6M |
| Mar 19, 2026 | George Lloyd Officer |
36,518 | $1.7M |
| Mar 18, 2026 | George Lloyd Officer |
100,462 | $4.6M |
| Mar 4, 2026 | George Lloyd Officer |
136,980 | $6.5M |
| Mar 2, 2026 | Terrance Coyne Officer |
34,791 | $1.7M |
| Feb 23, 2026 | Terrance Coyne Officer |
34,791 | $1.6M |
| Feb 3, 2026 | Terrance Coyne Officer |
135,117 | $5.8M |
| Feb 2, 2026 | Terrance Coyne Officer |
108,424 | $4.6M |
| Jan 20, 2026 | Terrance Coyne Officer |
69,582 | $2.7M |
| Jan 7, 2026 | George Lloyd Officer |
495,860 | $20.5M |
| Jan 2, 2026 | Terrance Coyne Officer |
69,582 | $2.7M |
| Dec 16, 2025 | Sandy Lamm LLC Officer |
160,000 | $6.1M |
| Dec 15, 2025 | Terrance Coyne Officer |
69,582 | $2.7M |
| Dec 1, 2025 | Urist Marshall Officer |
36,484 | $1.5M |
| Dec 1, 2025 | Terrance Coyne Officer |
69,582 | $2.8M |
| Dec 1, 2025 | Sandy Lamm LLC Officer |
46,667 | $930K |
| Nov 24, 2025 | Terrance Coyne Officer |
69,582 | $2.8M |
| Nov 19, 2025 | George Lloyd Officer |
355,426 | $13.7M |
| Nov 17, 2025 | Terrance Coyne Officer |
69,594 | $2.7M |
Show the other 29 notices
From the Form 144 XML filed with the SEC, since Nov 17, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RPRX/export.csv") into a cell.